Louisiana State Employees Retirement System Acquires 100 Shares of Glaukos Co. (NYSE:GKOS)

Louisiana State Employees Retirement System raised its stake in shares of Glaukos Co. (NYSE:GKOS) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,700 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Glaukos were worth $4,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of GKOS. Values First Advisors Inc. bought a new stake in shares of Glaukos in the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd lifted its stake in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the last quarter. KBC Group NV boosted its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the period. EWA LLC bought a new position in shares of Glaukos during the third quarter valued at about $209,000. Finally, Procyon Advisors LLC purchased a new position in shares of Glaukos in the third quarter worth about $210,000. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Stifel Nicolaus lifted their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, BTIG Research lifted their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $151.08.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,328 shares of company stock valued at $2,289,521. Insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS stock opened at $143.80 on Thursday. The company’s 50-day moving average is $151.20 and its 200 day moving average is $137.79. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $7.93 billion, a price-to-earnings ratio of -47.62 and a beta of 1.04.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.